Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Krystal Biotech ( (KRYS) ) just unveiled an announcement.
At its May 15, 2026 annual meeting of stockholders, Krystal Biotech shareholders re-elected Krish S. Krishnan and Christopher Mason as Class III directors to new three-year terms, reinforcing continuity on the company’s board. Investors also ratified KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026, signaling ongoing confidence in the company’s financial reporting oversight.
Stockholders approved, on a non-binding basis, the executive compensation program for the fiscal year ended December 31, 2025, indicating broad support for management’s pay structure. In addition, unaffiliated stockholders backed the company’s Non-Employee Director Compensation Policy, a vote that may ease governance concerns linked to ongoing litigation and underscores shareholder approval of the board’s remuneration framework.
The most recent analyst rating on (KRYS) stock is a Buy with a $310.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
Spark’s Take on KRYS Stock
According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.
Score is driven by strong financial performance (high margins, robust free cash flow, very low leverage) and a largely positive earnings call featuring solid commercial growth and a catalyst-rich pipeline. Technicals are supportive with an uptrend and positive momentum indicators. Valuation is the key restraint given the elevated P/E and lack of dividend yield.
To see Spark’s full report on KRYS stock, click here.
More about Krystal Biotech
Krystal Biotech, Inc. is a biotechnology company focused on developing genetic medicines, operating in the biopharmaceutical sector with a primary emphasis on innovative therapies for serious diseases. The company is publicly traded and governed by a board of directors elected by its stockholders, reflecting typical U.S. corporate governance structures in the life sciences industry.
Average Trading Volume: 287,032
Technical Sentiment Signal: Buy
Current Market Cap: $8.6B
See more data about KRYS stock on TipRanks’ Stock Analysis page.